[1] 李慧杰.健脾肾助长方辅助重组人生长激素治疗小儿特发性矮小症的效果观察[J].中国中医药科技,2022,29(2):247-248.
[2] 吴睿峰,庄承.肝脾补益法联合rhGH治疗ISS骨骼增长量的长期随访研究[J].重庆医学,2022,51(15):2605-2608.
[3] 郭艳艳,蒋成霞,姚兰,等.不同剂量重组人生长激素治疗对特发性矮小症患儿身高、体重以及血清IGF-1和IGFBP-3表达的影响[J].解放军医药杂志,2020,32(3):44-47.
[4] PALTOGLOU G,DIMITROPOULOS I,KOURLABA G,et al.The effect of treatment with recombinant human growth hormone(rhGH) on linear growth and adult height in children with idiopathic short stature(ISS):a systematic review and meta-analysis[J].J Pediatr Endocrinol Metab,2020,33(12):1577-1588.
[5] 胡玲,黎小年.重组人生长激素对特发性矮小症患儿血清Ghrelin及胰岛素样生长因子-1水平的影响[J].中国现代医学杂志,2019,29(15):108-111.
[6] 舒静娜,祁建凤.重组人生长激素对特发性矮小症患儿胰岛素样生长因子-1、胰岛素样生长因子结合蛋白-3的影响[J].中国妇幼保健,2020,35(3):486-488.
[7] KIM M,KIM E Y,KIM E Y,et al.Investigating whether serum IGF-1 and IGFBP-3 levels reflect the height outcome in prepubertal children upon rhGH therapy:LG growth study database[J].PLoS One,2021,16(11):e0259287.
[8] JOHANNSSON G,BIDLINGMAIER M,BILLER B M K,et al.Growth Hormone Research Society perspective on biomarkers of GH action in children and adults[J].Endocr Connect,2018,7(3):R126-R134.
[9] BALLERINI M G,BRASLAVSKY D,SCAGLIA P A,et al.Circulating IGF-I,IGFBP-3 and the IGF-I/IGFBP-3 molar ratio concentration and height outcome in prepubertal short children on rhGH treatment over two years of therapy[J].Horm Res Paediatr,2017,88(5):354-363.
[10] 江载芳,申昆玲,沈颖.诸福棠实用儿科学[M].8版.北京:人民卫生出版社,2015:102-105.
[11] 张一民.切实提高学生体质健康水平——《国家学生体质健康标准(2014年修订)》解读[J].体育教学,2014,34(9):5-11.
[12] BAYLEY N,PINNEAU S R.Tables for predicting adult height from skeletal age:revised for use with the Greulich-Pyle hand standards[J].J Pediatr,1952,40(4):423-441.
[13] PEREZ-COLON S,LAZAREVA O,PURUSHOTHAMAN R,et al.Baseline IGFBP-3 as the key element to predict growth response to growth hormone and IGF-1 therapy in subjects with non-GH deficient short stature and IGF-1 deficiency[J].Int J Endocrinol Metab,2018,16(3):e58928.
[14] SAVAGE M O,STORR H L,BACKELJAUW P F.The continuum between GH deficiency and GH insensitivity in children[J].Rev Endocr Metab Disord,2021,22(1):91-99.
[15] POLIDORI N,CASTORANI V,MOHN A,et al.Deciphering short stature in children[J].Ann Pediatr Endocrinol Metab,2020,25(2):69-79.
[16] GUTEFELDT K,HEDMAN C A,THYBERG I S M,et al.Dysregulated growth hormone-insulin-like growth factor-1 axis in adult type 1 diabetes with long duration[J].Clin Endocrinol(Oxf),2018,89(4):424-430.
[17] WITKOWSKA-SDEK E,KUCHARSKA A M,RUMISKA M,et al.Decreased thyroxine levels during rhGH Therapy in children with growth hormone deficiency[J].J Clin Med,2021,10(21):5100-5107.
[18] MEINHARDT U J,HO K K.Modulation of growth hormone action by sex steroids[J].Clin Endocrinol(Oxf),2006,65(4):413-422.
[19] HAN W,ZHANG J,SONG T,et al.Significance of recombinant human growth hormone therapy in promoting growth and development of children with idiopathic short stature[J].Pak J Med Sci,2022,38(7):2016-2020.
[20] CIANFARANI S.Risk of cancer in patients treated with recombinant human growth hormone in childhood[J].Ann Pediatr Endocrinol Metab,2019,24(2):92-98.
[21] LU T,FORGETTA V,WU H,et al.A polygenic risk score to predict future adult short stature among children[J].J ClinEndocrinol Metab,2021,106(7):1918-1928. |